Market Research Report
Investigation Report on China's Loratadine Market, 2018-2022
|Published by||China Research and Intelligence||Product code||332768|
|Published||Content info||30 Pages
Delivery time: 1-2 business days
|Investigation Report on China's Loratadine Market, 2018-2022|
|Published: December 13, 2018||Content info: 30 Pages||
The incidences of common skin redness, itching and rashes and respiratory allergies are rising as China's economy develops, the living environment and dietary structure change, and environmental pollution intensifies, which drives the growth of the antihistamine market.
As a second-generation antihistamine, Loratadine is a common H1 receptor antagonist used to relieve the symptoms of allergic rhinitis, eye itching and burning sensation, and the symptoms and signs of chronic urticaria, pruritic skin diseases and other allergic skin diseases. It can quickly relieve nose and eye allergies. Moreover, Loratadine has a low affinity for the H1 receptor of the central nervous system, and thus has hardly any side effect on the nervous system.
Developed by Schering-Plough which has been acquired by Bayer, Loratadine (trade name: Clarityne) was first launched in Belgium in 1988 and then sold in several European countries. In Apr. 1993, it was approved by the FDA to be marketed in the U.S. In Sept. 2002, it was launched in Japan. In November of the same year, the FDA approved Clarityne as a non-prescription drug.
According to CRI, in Jun. 1993, imported Loratadine tablets were approved to be sold in China under the trade name Clarityne. In 2005, the CFDA approved Clarityne as a non-prescription drug for its excellent effect and long-tested safety. Many Chinese companies have launched generic Loratadine products in the dosage forms of oral tablets, capsules, granules, syrup and compound preparation. The market competition is fierce but the brand-name drug still has great advantages. In 2017, Shanghai Schering-Plough Pharmaceutical Co., Ltd. And Schering-Plough occupied about 65% market share by sales value. But the market share of the brand-name drug showed a downward trend.
Loratadine has secured a place on the market by advantage of long-lasting and quick-acting effect and rare adverse reactions. However, with the increasing number of Loratadine manufacturers and intensifying competition on the market, the average price of Loratadine is declining.
It is expected that as the incidences of allergic diseases continue to increase, China's Loratadine market will still have some growth potential in the next few years.